425: CoreWeave CEO Updates on Core Scientific Acquisition, Highlights Regulatory Filings and Risks

CoreWeave's CEO, Michael Intrator, posted a LinkedIn update on the proposed acquisition of Core Scientific, emphasizing the need for investors to review official SEC filings for detailed transaction information and outlining associated risks.

Summary

• The communication is a LinkedIn post by CoreWeave CEO Michael Intrator on July 7, 2025, regarding CoreWeave's proposed acquisition of Core Scientific.
• CoreWeave and Core Scientific will file relevant materials with the SEC, including a Form S-4 registration statement by CoreWeave that will include a proxy statement of Core Scientific and also constitute a prospectus of CoreWeave.
• A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific.
• Investors and security holders are urged to read the registration statement, proxy statement/prospectus, and any other relevant documents filed with the SEC carefully and in their entirety when they become available.
• Free copies of these documents will be available from the SEC's website, CoreWeave's website, and Core Scientific's website.
• CoreWeave, Core Scientific, their respective directors, and certain executive officers may be deemed participants in the solicitation of proxies for the proposed transaction.
• The communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities or a solicitation of any vote or approval.
• The communication contains forward-looking statements that are subject to various risks, uncertainties, and assumptions.

Sentiment

Score: 5

Explanation: The filing is a standard legal disclosure related to a proposed acquisition, providing procedural information and extensive risk factors without presenting specific positive or negative financial outcomes.

Risks

• Completion of the proposed transaction on anticipated terms, or at all, and timing of completion, including obtaining required regulatory approvals on anticipated terms and Core Scientific stockholder approval.
• Anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the combined company's operations.
• The possibility that any of the anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period.
• The ability of CoreWeave and Core Scientific to integrate their businesses successfully and to achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against CoreWeave, Core Scientific, or their respective directors and officers.
• Disruptions from the proposed transaction harming CoreWeave's or Core Scientific's business, including current plans and operations, and diversion of management's time and attention on transaction-related issues.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Rating agency actions and CoreWeave's and Core Scientific's ability to access shortand long-term debt markets on a timely and affordable basis.
• Legislative, regulatory, and economic developments and actions targeting public companies in the artificial intelligence, power, data center, and crypto mining industries, and changes in local, national, or international laws, regulations, and policies.
• Potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction.
• Certain restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions or otherwise operate its business.
• Acts of terrorism or outbreak of war, hostilities, civil unrest, attacks against CoreWeave or Core Scientific, and other political or security disturbances.
• Dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction.
• The possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• The impacts of pandemics or other public health crises, including the effects of government responses on people and economies.
• Global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing.
• Changes in technical or operating conditions, including unforeseen technical difficulties.
• Development delays at CoreWeave and/or Core Scientific data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites.
• Other risks described in CoreWeave's Prospectus dated March 27, 2025, and its Quarterly Report on Form 10-Q for the period ended March 31, 2025, and subsequent reports.
• Other risks described in Core Scientific's Quarterly Report on Form 10-Q for the period ended March 31, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent reports.
• Risks that will be described in the registration statement on Form S-4 and accompanying prospectus.

Future Outlook

The document outlines the procedural steps for the proposed acquisition of Core Scientific by CoreWeave, including the future filing of a Form S-4 registration statement and proxy statement/prospectus. It anticipates the realization of benefits and synergies from the transaction, though these are subject to significant risks such as regulatory approvals, successful business integration, and market conditions. The combined entity's future operations may involve converting crypto mining facilities to high-performance computing sites.

Management Comments

• The communication was posted on LinkedIn by Michael Intrator, Chief Executive Officer of CoreWeave, Inc., on July 7, 2025, in connection with CoreWeave's proposed acquisition of Core Scientific, Inc.

Industry Context

The proposed acquisition and the mention of converting crypto mining facilities to high-performance computing sites suggest a strategic move within the data center and AI infrastructure sectors. This aligns with a broader industry trend of increasing demand for AI and high-performance computing capabilities, potentially indicating a diversification or pivot away from traditional crypto mining operations for Core Scientific under CoreWeave's ownership.

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against CoreWeave, Core Scientific, or their respective directors and officers.

Stakeholder Impact

• Shareholders of Core Scientific will need to vote on the proposed transaction and will receive a definitive proxy statement/prospectus.
• Shareholders of CoreWeave face potential dilution due to the issuance of additional shares of its securities in connection with the proposed transaction.
• Management and employees of both CoreWeave and Core Scientific may experience diversion of time and attention on transaction-related issues and potential disruptions to current plans and operations.
• Business relationships of both companies may face potential adverse reactions or changes resulting from the announcement or completion of the proposed transaction.

Next Steps

• CoreWeave and Core Scientific will file relevant materials with the SEC, including a Form S-4 registration statement and a proxy statement/prospectus.
• A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific.
• Investors and security holders are urged to read the registration statement, proxy statement/prospectus, and other relevant documents when they become available.
• Additional information regarding participants in proxy solicitations and their direct or indirect interests will be contained in the proxy statement/prospectus.
• The proposed transaction requires obtaining regulatory approvals and Core Scientific stockholder approval.

Key Dates

Keywords

CoreWeave, Core Scientific, Acquisition, Merger, SEC Filing, Form 425, Proxy Statement, Prospectus, S-4, Corporate Governance, Risk Factors, Artificial Intelligence, Data Center, High-Performance Computing, Crypto Mining